Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.62 |
| ▸ | CASP1 | P29466 | 2/20 | 0.62 |
| ▸ | CASP7 | P55210 | 2/20 | 0.62 |
| ▸ | CASP9 | P55211 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988598 | 0.86 | CASP3 (0.79) | CASP3CASP1CASP7CASP9BRD4 | |
| SCHEMBL5750147 | 0.77 | CA1 (0.51) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL2486952 | 0.77 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL31395806 | 0.77 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL6535562 | 0.76 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL6535690 | 0.76 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL31175908 | 0.76 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL5989268 | 0.75 | CDK5 (0.50) | ALDH1A1TSHRHPGD | |
| SCHEMBL5750167 | 0.73 | GAA (0.78) | SMN1; SMN2 | |
| SCHEMBL30555459 | 0.71 | CASP3 (0.81) | CASP3CASP1CASP7CASP9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CASP3 2466/4885CASP1 1681/4885CASP7 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.